PNAS:NUS1的编码突变导致帕金森病

2018-10-23 MedSci MedSci原创

帕金森病(Parkinson’s disease,PD)是世界上第二常见的神经退行性疾病(Neurodegenerative disease,ND)。之前已经发现了几种常见和罕见的与PD发病机制相关的遗传风险变异,但主要基于欧洲血统的人群,对汉族人来说,家族性PD的遗传贡献在很大程度上是目前仍然是未知的。 在本项研究中,研究人员提出了一项以三人组为基础的研究以探讨de - novoa改变基因

帕金森病(Parkinson’s diseasePD)是世界上第二常见的神经退行性疾病(Neurodegenerative diseaseND)。之前已经发现了几种常见和罕见的与PD发病机制相关的遗传风险变异,但主要基于欧洲血统的人群,对汉族人来说,家族性PD的遗传贡献在很大程度上是目前仍然是未知的。

在本项研究中,研究人员提出了一项以三人组为基础的研究以探讨de - novoa改变基因与汉族早期PD的关系,进而挖掘中国汉族PD患者人群新的遗传风险基因。研究者对19个三人组(父母和患有早发性帕金森病)(EOPD)的孩子)和20个四人组(父母和他们的两个孩子:一个患有EOPD,另一个是健康的)进行外显子测序,发现12个发生了胚系突变(de novo功能性突变)基因(MAD1L1, NUP98, PPP2CB, PKMYT1, TRIM24, CEP131,CTTNBP2, NUS1, SMPD3, MGRN1, IFI35, RUSC2)。研究发现12个具有新生突变的基因在生物学上相互联系,它们很可能是疾病风险基因。通过对两个独立群组的进一步分析发现NUS1含有更多罕见的非同义变异,随后对果蝇的功能研究证实了其与PD发病机制的潜在联系。在果蝇的功能研究表明,NUS1的丧失可以降低攀爬能力、多巴胺水平、多巴胺能神经元的数量,同时诱导果蝇大脑的细胞凋亡事件。这些结果表明,de novo突变对早发性PD发病机理的影响,并且确定NUS1PD的一个新的候选致病基因。

原始出处:

Ji-feng Guo, Lu Zhang, Kai Li,Coding mutations in NUS1 contribute to Parkinson’s disease

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1225595, encodeId=93e7122559586, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Jun 10 09:39:21 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216133, encodeId=af0a121613328, content=<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48520, encryptionId=a1f9485204d, topicName=帕金森病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun May 01 19:07:54 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856232, encodeId=49ad1856232f7, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 05 21:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584720, encodeId=7cc21584e208d, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Oct 25 13:54:00 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2022-06-10 屋顶瞄爱赏月

    签到学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1225595, encodeId=93e7122559586, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Jun 10 09:39:21 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216133, encodeId=af0a121613328, content=<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48520, encryptionId=a1f9485204d, topicName=帕金森病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun May 01 19:07:54 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856232, encodeId=49ad1856232f7, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 05 21:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584720, encodeId=7cc21584e208d, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Oct 25 13:54:00 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1225595, encodeId=93e7122559586, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Jun 10 09:39:21 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216133, encodeId=af0a121613328, content=<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48520, encryptionId=a1f9485204d, topicName=帕金森病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun May 01 19:07:54 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856232, encodeId=49ad1856232f7, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 05 21:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584720, encodeId=7cc21584e208d, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Oct 25 13:54:00 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2019-05-05 drwjr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1225595, encodeId=93e7122559586, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Jun 10 09:39:21 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216133, encodeId=af0a121613328, content=<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48520, encryptionId=a1f9485204d, topicName=帕金森病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun May 01 19:07:54 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856232, encodeId=49ad1856232f7, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 05 21:54:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584720, encodeId=7cc21584e208d, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Oct 25 13:54:00 CST 2018, time=2018-10-25, status=1, ipAttribution=)]

相关资讯

日本尝试用诱导多能干细胞治疗帕金森病

日本研究人员于7月30日宣布将启动一项临床试验,利用从诱导多能干(iPS)细胞中提取的神经物质治疗帕金森病,这将是iPS细胞首次被用于治疗人类帕金森病。研究人员要用iPS细胞培养神经前体细胞,再将这些能分化成神经细胞的前体细胞移植到帕金森病患者脑部,以试验这种方法治疗帕金森病的有效性和安全性。

Neurology:糖尿病与后续帕金森病之间的关系

由此可见,在这项大型队列研究中,研究人员报告了T2DM后PD的发生率有所增加。这些发现可能反映了他们可能共享遗传易感性和/或共享致病途径,这些结果具有潜在的临床和治疗意义。

SCI REP:开角型青光眼与阿尔茨海默氏症和帕金森病的风险

由此可见,诊断为OAG的患者发生AD的风险增高,但与PD无关,并且风险因年龄和性别有所不同。

eLife:对帕金森病理论提出质疑

早在200多年前,一位英国医生首次描述了帕金森氏症,这种神经退行性疾病的确切病因尚不明确。最近,《eLife》一项由巴塞尔大学Henning Stahlberg领导的研究指出,之前我们对这种疾病的理解可能是错误的。

视网膜可用于检测帕金森病

据新华社马德里 5 月 27 日电 西班牙研究人员日前报告说,他们首次在视网膜上检测到了与帕金森病发病密切相关的阿尔法—突触核蛋白,这一发现有望应用于帕金森病等神经退行性疾病的早期诊断。

III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病(PD)患者的持续运动波动

III期临床TOLEDO是第一个多中心、随机、双盲试验,研究其在PD中的疗效和安全性,并在来自7个国家的23家医院的107名患者中进行,这些PD患者尽管服用了多种药物,但症状仍未得到有效控制。